Characteristics of Analgesic Patch Formulations

References

• Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65(1):39–44. doi:10.1016/0304-3959(95)00146-8
   PubMed Web of Science ®Google Scholar
• Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. The Journal of Pain. 2017;18:42–53.
   PubMed Web of Science ®Google Scholar
• Endo Pharmaceuticals Inc. Lidoderm (Lidocaine Patch 5%) Prescribing Information. MalvernPA: Endo Pharmaceuticals Inc; 2015.
   Google Scholar
• Scilex Pharmaceuticals Inc. ZTLIDO (Lidocaine Topical System) Prescribing Information. San Diego, CA: Scilex Pharmaceuticals Inc; 2018.
   Google Scholar
• Pfizer Inc. Flector (Diclofenac Epolamine Topical System) Prescribing Information. Pfizer Inc: New York, NY; 2019.
   Google Scholar
• Galen US Inc. Synera ^®(Lidocaine and Tetracaine) Topical Patch Prescribing Information. Souderton, PA: Galen US Inc; 2018.
   Google Scholar
• NeurogesX, Inc. Qutenza ^® (Capsaicin 8% Patch) Prescribing Information. San Mateo, CA:NeurogesX, Inc.
   Google Scholar
• Janssen Pharmaceuticals, Inc. Duragesic (Fentanyl Transdermal System) Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2018.
   Google Scholar
• Purdue Pharma L.P. Butrans ^® (Buprenorphine Transdermal System) Prescribing Information. Stamford, CT: Purdue Pharma L.P; 2014.
   Google Scholar
• Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. Skin Res and Tech. 2008;14:249–260. doi:10.1111/j.1600-0846.2008.00316.x
   PubMed Web of Science ®Google Scholar
• Mathews L, Roy A. Management of pain using transdermal patches – A review. Asian J Pharmaceutical Clin Res. 2016;9:32–335.
   Google Scholar
• Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. Br J Pharmacol. 2015;172:2179–2209.
   PubMed Web of Science ®Google Scholar
• Lisi DM. OTC Transdermal analgesic patches in pain management. US Pharm. 2019;44:15–21.
   Web of Science ®Google Scholar
• Durand C, Alhammad A, Willett KC. Practical considerations for optional transdermal drug delivery. Am J Health Syst Pharm. 2012;69:116–124.
   PubMed Web of Science ®Google Scholar
• Hughes PJ, Freeman MK, Wensel TM. Appropriate use of transdermal drug delivery systems. J Nurs Edu Pract. 2013;3:129–138.
   PubMedGoogle Scholar
• Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LF. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharmaceutics Biopharmaceutic. 2006;64:1–8.
   PubMed Web of Science ®Google Scholar
• Bajaj S, Whiteman A, Brandner B. Transdermal drug delivery in pain management. Continu Educ Anaesthesia Critical Care Pain. 2011;11:39–43.
   Google Scholar
• Fentanyl Transdermal System. Prescribing Information. Bedminster, NJ: Mallinckrodt Pharmaceuticals; 2018.
   Google Scholar
• Hong I, Gabay M, Lodolce A. Safety concerns involving transdermal patches and magnetic resonance imaging (MRI). Hosp Pharm. 2010;45:771–778.
   Google Scholar
• Wilbur RL The Difference Between Topical and Transdermal Medications. 2017 Genesco Pharma. Miami, FL. Available from: https://genscopharma.com/difference-topical-transdermal-medications/. Accessed April 2, 2020.
   Google Scholar
• Madison KC. Barrier function of the skin: “La Raison d’Etre” of the Epidermis. J Invest Dermatol. 2003;121:231–241.
   PubMed Web of Science ®Google Scholar
• Roy N, Agrawal M, Chaudhary S, Tirkey V, Dhwah A, Mishra N. Review article on permeation enhancers: a major breakthrough in drug delivery technology. Int J Pharmaceutical Sci and Res. 2017;8:1001–1011.
   Web of Science ®Google Scholar
• Nalamachu S, Gould EM, Gammaitoni AR. Use of the lidocaine patch 5% in the treatment of neuropathic pain. J Neuropathic Pain Symptom Palliation. 2006;2:3–13.
   Google Scholar
• Cilurzo F, Gennari CGM, Minghetti P. Adhesive properties: a critical issue in transdermal patch development. Expert Opin Drug Deliv. 2012;9:33–45.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Guidelines on quality of transdermal patches 2014. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-transdermal-patches_en.pdf. Accessed: April 2, 2020.
   Google Scholar
• US Food and Drug Administration. Assessing adhesion with transdermal and topical delivery systems for ANDAs – guidance for Industry (Draft Guidance); 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-adhesion-transdermal-delivery-systems-and-topical-patches-andas-draft-guidance-industry. Accessed May 1, 2020.
   Google Scholar
• Gudin J, Nalamachu S. Utility of lidocaine as a topical analgesic and improvements in patch delivery systems. Postgrad Med. 2020;132:28–36.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for Industry Residual Drug in Transdermal and Related Drug Delivery Systems; 2011. Available from: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed Jan 5, 2020.
   Google Scholar
• US Food and Drug Administration. Fentanyl Patch Can Be Deadly to children; 2012. Available from: https://www.fda.gov/consumers/consumer-updates/fentanyl-patch-can-be-deadly-children. Accessed Jan. 5, 2020.
   Google Scholar
• Mylan Pharmaceuticals Inc. Lidocaine (Lidocaine Patch) Prescribing Information. Morgantown, WV: Mylan Pharmaceuticals Inc; 2018.
   Google Scholar
• US Food and Drug Administration. Abbreviated New Drug Application (ANDA). 2019 Available from: https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda. Accessed May 1, 2020.
   Google Scholar
• Gudin J, Nalamachu S, Argoff C, et al. Adhesion Performance of 3 Lidocaine Patch Formulations. Las Vegas, NV: Presented at PAINWeek; 2018.
   Google Scholar
• Sheets MF, Hanck DA. Outward stabilization of the S4 segments in domains III and IV enhances lidocaine block of sodium channels. J Physiol. 2007;582::317–334. 317.
   PubMed Web of Science ®Google Scholar
• Mick G, Correa-Illanes G. Topical pain management with the 5% lidocaine medicated plaster – a review. Curr Med Res Opin. 2012;28(6):937–951.
   PubMed Web of Science ®Google Scholar
• Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533–538.
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol. 1995;37:246–253.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Adverse Events Reporting System (FAERS) Public Dashboard. 2018. Available at: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed July 27, 2018.
   Google Scholar
• US Food and Drug Administration. FDA Adverse Events Reporting System 9FAERS Public Dashboard; 2018. Available from: https://www.fda.gov/drugs/fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files. Accessed February 13, 2020.
   Google Scholar
• Drugs.com User Reviews for Lidoderm. Available from: https://www.drugs.com/comments/lidocaine-topical/lidoderm.html. Accessed September 12, 2019.
   Google Scholar
• Drugs.com User Reviews for Topical Lidocaine. Available from: https://www.drugs.com/comments/lidocaine-topical/. Accessed Nov.17, 2019.
   Google Scholar
• PissedConsumer.com Mylan Lidocaine Transdermal Patch Reviews and Complaints. Available from:: https://mylan.pissedconsumer.com/mylan-lidocaine-transdermal-patch-4455/complaints/RT-CP.html. Accessed Nov 18, 2019.
   Google Scholar
• EMLA Cream, EMLA Patch. Product Monograph. Toronto, Ontario: Aspen Pharmacare Canada, Inc; 2017.
   Google Scholar
• Baranidharan G, Das S, Bhaskar A. A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain. Ther Adv Neurol Disord. 2013;6:287–297.
   PubMed Web of Science ®Google Scholar
• Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107:490–502.
   PubMed Web of Science ®Google Scholar
• Polydefkis M, Hauer P, Sheth S, et al. The time course of epidermal nerve fiber regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain. 2004;127:1606–1615.
   PubMed Web of Science ®Google Scholar
• Mou J, Paillard F, Turnbull B, et al. Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. Pain. 2013;154:1632–1639.
   PubMed Web of Science ®Google Scholar
• Zeng C, Wei J, Persson MSM, et al. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. Br J Sports Med. 2018;52:642–650.
   PubMed Web of Science ®Google Scholar
• Food US, Administration D. External analgesic drug products for over-the-counter human use; Tentative final monograph. Fed Regist. 1983;48(No.27):5852.
   Google Scholar
• Food US, Administration D. External analgesic drug products for over-the-counter human use; reopening of the administrative record and amendment of tentative final monograph. Fed Regist. 2003;68:42324.
   Google Scholar
• Food US, Administration D. Mayne Pharma Group Limited and Actavis Laboratories UT, Inc.; Withdrawal of Approval of Abbreviated New Drug Applications for Fentanyl Transdermal Systems. Fed Regist. 2019;84:63660.
   Google Scholar
• Arnet I, Schacher S, Balmer E, Koeberle D, Hersberger KE. Poor adhesion of fentanyl transdermal patches may mimic end-of-dosage failure after 48 hours and prompt early patch replacement in hospitalized cancer pain patients. J Pain Relief. 2016;9:993–999.
   Google Scholar
• Kathe K, Kathpolia H. Film forming systems for topical and transdermal drug delivery. Asian J Pharmaceut Sci. 2017;12:487–497.
   PubMed Web of Science ®Google Scholar
• Zhao X, Sun Y, Li Z. Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system. Drug Des Devel Ther. 2018;12:4231–4240.
   PubMed Web of Science ®Google Scholar
• Ita K. Perspectives on transdermal electroporation. Pharmaceutics. 2016;8:9. doi:10.3390
   PubMed Web of Science ®Google Scholar
• Tuan-Mahmood T-M, McCrudden MTC, Torrisi BM, et al. Microneedles for intradermal and transdermal delivery. Eur J Pharm Sci. 2013;50:623–637.
   PubMed Web of Science ®Google Scholar